Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 3 Japan Generic Majors Log 6% Growth in Combined April-September Sales despite Price Revision
November 20, 2018
- Fuji Pharma to Bolster Biosimilar Business as New Core
November 20, 2018
- High Court Upholds Not-Guilty Ruling for Novartis, Ex-Employee in Diovan Case
November 20, 2018
- Toray to Develop Small Molecule Cancer Drug Licensed from US Bioventure
November 20, 2018
- Chugai Sues Alexion in US over Soliris Successor ALXN1210
November 19, 2018
- 4 Major Wholesalers See 46.1% Increase in 1st Half Operating Profit due to Reductions in Yakkasa and SGA Costs
November 19, 2018
- Takeda to Procure €7.5 Billion in Bonds for Shire Acquisition
November 19, 2018
- AstraZeneca Japan Set to Roll Out 4 New Treatments Every Year through 2021: Chief
November 16, 2018
- Talion AG Contributes to Nipro’s Strong Generic Biz Growth
November 16, 2018
- Novo to Develop New Dosages for Ozempic, 14-Day Prescription Limit Weighs
November 16, 2018
- NapaJen Pharma Initiates PI Trial of Oligonucleotide Therapeutic in Australia
November 16, 2018
- Hib Vaccine Wind-Up, Development Flop Trigger GSK, Daiichi Sankyo to Shutter JV
November 15, 2018
- Meiji Seika Pharma to Venture into Eye-Care Field in Indonesia in Collaboration with Santen
November 15, 2018
- Nichi-Iko Places Top Priority on Product Launches in the US in Biosimilar Business: President
November 14, 2018
- GSK, Daiichi Sankyo Dissolve Vaccine JV
November 14, 2018
- Sumitomo Dainippon Establishes JV with Sumitomo Bakelite through Transfer of Diagnostics Biz
November 13, 2018
- Santen Aims at 1st-Line Use of Eybelis for Glaucoma Treatment: President
November 13, 2018
- Big Takeda Could Debut as Early as January 8, De-facto Vote on Shire Deal Set for Dec. 5
November 13, 2018
- Takeda: De-facto Vote on Shire Deal Set for Dec. 5
November 12, 2018
- Japan Is Top Strategic Market for Biogen: CEO
November 12, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…